MarketCap
Facebook
X
TelegramAnnual report 2024
added 04-25-2026
Inventiva S.A. EV/EBITDA Ratio 2011-2026 | IVA
Annual EV/EBITDA Ratio Inventiva S.A.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.77 | -8.57 | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.57 | -9.77 | -9.17 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
4.1 | $ 95.5 | -3.88 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Cerus Corporation
CERS
|
-24.7 | $ 2.59 | -4.78 % | $ 494 M | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-3.66 | - | - | $ 269 M | USA |
 |
Cardiff Oncology
CRDF
|
-8.15 | $ 1.61 | -2.42 % | $ 108 M | USA |
 |
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
76.5 | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-16.9 | - | -7.31 % | $ 87 M | USA |
 |
Cue Biopharma
CUE
|
-7.01 | $ 34.94 | 17.05 % | $ 3.31 B | USA |
 |
Calithera Biosciences
CALA
|
-7.96 | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-1.63 K | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-0.721 | - | - | $ 3.74 B | USA |
 |
Editas Medicine
EDIT
|
-6.41 | $ 3.04 | 1.33 % | $ 270 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
0.677 | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.0315 | - | - | $ 231 M | USA |
 |
Exelixis
EXEL
|
18.1 | $ 44.42 | 0.57 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
-21.1 | $ 22.35 | 0.72 % | $ 3.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-5.59 | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-1.5 | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
12.8 | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-1.56 | - | - | $ 28.6 M | USA |
 |
Galapagos NV
GLPG
|
-26.5 | $ 28.39 | -0.13 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
13.7 | $ 8.27 | 0.49 % | $ 6.83 B |  Spain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-43.1 | $ 3.5 | 5.42 % | $ 5.76 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
-2.63 | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
0.296 | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-20.4 | - | -11.43 % | $ 502 K | USA |
 |
ImmuCell Corporation
ICCC
|
23.1 | $ 8.87 | 1.66 % | $ 80.1 M | USA |
 |
InflaRx N.V.
IFRX
|
-3.65 | $ 1.97 | -7.51 % | $ 152 M | Germany |
 |
Applied Therapeutics
APLT
|
-0.476 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |